Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 02, 2026 08:30 ET | Source: Biodexa Pharmaceuticals PLC

Biodexa Announces Partnership with Syngene To Manufacture MTX240 GMP Clinical Trial Supplies

April 2, 2026 Biodexa Announces Partnership with Syngene To Manufacture MTX240 GMP Clinical Trial Supplies Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) (“Biodexa” or “Company”), a clinical stage...
March 27, 2026 17:00 ET | Source: Biodexa Pharmaceuticals PLC

Preliminary Results for the Year Ended 31 December 2025

March 27, 2026 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company” or, together with its subsidiaries, the “Group”) Preliminary Results for the Year Ended 31 December 2025 Biodexa...
February 04, 2026 08:30 ET | Source: Biodexa Pharmaceuticals PLC

Biodexa Announces Exclusive License of Otsuka’s OPB-171775, a potent Phase 1 ready Molecular Glue for GIST

February 4, 2026 Biodexa Announces Exclusive License of Otsuka’s OPB-171775, a potent Phase 1 ready Molecular Glue for GIST Novel Mechanism of Action Shown to be Effective in TKI Resistant PDX...
April 15, 2025 13:00 ET | Source: DelveInsight Business Research LLP

Gastrointestinal Stromal Tumor Market to Grow Rapidly During the Study Period (2020–2034) Owing to the Launch of Emerging Therapies | DelveInsight

New York, USA, April 15, 2025 (GLOBE NEWSWIRE) -- Gastrointestinal Stromal Tumor Market to Grow Rapidly During the Study Period (2020–2034) Owing to the Launch of Emerging Therapies | DelveInsight ...
October 19, 2022 13:00 ET | Source: DelveInsight Business Research LLP

24+ Key Companies Actively Working in the Gastrointestinal Stromal Tumor Pipeline Segment | DelveInsight

New York, USA, Oct. 19, 2022 (GLOBE NEWSWIRE) -- 24+ Key Companies Actively Working in the Gastrointestinal Stromal Tumor Pipeline Segment | DelveInsight Gastrointestinal stromal tumors (GISTs) are...